Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 2
1992 3
1995 2
1997 3
1998 2
1999 3
2000 6
2001 4
2002 2
2003 4
2004 6
2005 6
2006 1
2007 6
2008 6
2009 5
2010 5
2011 7
2012 2
2013 4
2014 2
2015 2
2016 2
2017 5
2018 5
2019 9
2020 19
2021 20
2022 16
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Castro M, et al. Among authors: corren j. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782217 Free article. Clinical Trial.
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Menzies-Gow A, et al. Among authors: corren j. N Engl J Med. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. N Engl J Med. 2021. PMID: 33979488 Clinical Trial.
Tezepelumab in Adults with Uncontrolled Asthma.
Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Corren J, et al. N Engl J Med. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. N Engl J Med. 2017. PMID: 28877011 Free article. Clinical Trial.
Targeting TSLP in Asthma.
Parnes JR, Molfino NA, Colice G, Martin U, Corren J, Menzies-Gow A. Parnes JR, et al. Among authors: corren j. J Asthma Allergy. 2022 Jun 3;15:749-765. doi: 10.2147/JAA.S275039. eCollection 2022. J Asthma Allergy. 2022. PMID: 35685846 Free PMC article. Review.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Among authors: corren j. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. Among authors: corren j. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist Å, Roseti SL, Molfino NA, Llanos JP, Martin N, Bowen K, Griffiths JM, Parnes JR, Colice G. Corren J, et al. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC. Am J Respir Crit Care Med. 2023. PMID: 37015033 Free PMC article. Clinical Trial.
EAACI Biologicals Guidelines-Recommendations for severe asthma.
Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, Flood B, Firinu D, Gern JE, Hamelmann E, Hanania N, Hernández-Martín I, Knibb R, Mäkelä M, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Pfaar O, Quirce S, Sastre J, Shamji M, Schwarze J, Palomares O, Jutel M. Agache I, et al. Among authors: corren j. Allergy. 2021 Jan;76(1):14-44. doi: 10.1111/all.14425. Epub 2020 Aug 10. Allergy. 2021. PMID: 32484954
Conjunctivitis in dupilumab clinical trials.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A. Akinlade B, et al. Among authors: corren j. Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7. Br J Dermatol. 2019. PMID: 30851191 Free PMC article.
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Hernández-Martín I, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Agache I, et al. Among authors: corren j. Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24. Allergy. 2020. PMID: 32034960
165 results